Payment overview · 2025
General Payments
$408.26
12 reported records · 8 companies
Healthcare provider profile · identity verified
Stanislav V Byshenko, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SHARON, PA · NPI 1891088415
Verified facts
What the public records show
CMS Open Payments records show Stanislav V Byshenko, MD received $408.26 in general payments during 2025 across 12 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 39.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $161.53 | 39.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $135.92 | 33.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $23.45 | 5.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.83 | 5.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.74 | 4.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.97 | 4.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.05 | 3.9% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $15.77 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $408.26 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $161.53 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $135.92 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $23.45 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $10.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 61 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
103 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 297 | 61 |
| Atorvastatin Calcium | Atorvastatin Calcium | 272 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 271 | 69 |
| Losartan Potassium | Losartan Potassium | 180 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 180 | 40 |
| Levothyroxine Sodium | Levothyroxine Sodium | 172 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 153 | 45 |
| Metformin Hcl | Metformin Hcl | 131 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 123 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 117 | 28 |
| Lisinopril | Lisinopril | 109 | 26 |
| Glipizide | Glipizide | 105 | 26 |
| Trulicity | Dulaglutide | 103 | 15 |
| Gabapentin | Gabapentin | 102 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 98 | 20 |
| Alendronate Sodium | Alendronate Sodium | 95 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 95 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 75 | 25 |
| Tramadol Hcl | Tramadol Hcl | 70 | 13 |
| Potassium Chloride | Potassium Chloride | 69 | 15 |
| Pregabalin | Pregabalin | 69 | 11 |
| Omeprazole | Omeprazole | 68 | 22 |
| Valsartan | Valsartan | 68 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 19 |
| Mounjaro | Tirzepatide | 61 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | suppressed |
| Eliquis | Apixaban | 58 | suppressed |
| Jardiance | Empagliflozin | 56 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 20 |
| Carvedilol | Carvedilol | 52 | 11 |
| Allopurinol | Allopurinol | 45 | 12 |
| Simvastatin | Simvastatin | 45 | suppressed |
| Ozempic | Semaglutide | 44 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 42 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | suppressed |
| Repatha Sureclick | Evolocumab | 40 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 38 | suppressed |
| Lorazepam | Lorazepam | 38 | suppressed |
| Furosemide | Furosemide | 36 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | suppressed |
| Azithromycin | Azithromycin | 33 | 31 |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 28 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Nexletol | Bempedoic Acid | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Repatha Syringe | Evolocumab | 24 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Phenobarbital | Phenobarbital | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Meloxicam | Meloxicam | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Loperamide | Loperamide Hcl | 20 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 19 | 17 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 12 |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $408.26 · 12 records | Bayer Healthcare Pharmaceuticals Inc. | BREZTRI, Kerendia, MOUNJARO, OTEZLA, QULIPTA, REPATHA, REXULTI, TRINTELLIX, UBRELVY, ZEPBOUND, ZORYVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error